MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Adaptimmune Therapeutics PLC - Company Profile (NASDAQ:ADAP)

Consensus Ratings for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.00 (117.92% upside)

Analysts' Ratings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Show:
DateFirmActionRatingPrice TargetActions
4/24/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2016Deutsche BankInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015SunTrustInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015GuggenheimInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Bank of AmericaInitiated CoverageNeutral$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q1($0.19)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.20)($0.16)($0.18)
Q2 20163($0.26)($0.19)($0.22)
Q3 20162($0.31)($0.20)($0.26)
Q4 20162($0.40)($0.26)($0.33)
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.31)($0.31)($0.31)
(Data provided by Zacks Investment Research)
Dividend History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/24/2016Orbimed Advisors LlcDirectorBuy1,712,400$10.42$17,843,208.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Charles Elliott SigalDirectorBuy15,000$1.56$23,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Charles Elliott SigalDirectorBuy45,000$1.53$68,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
DateHeadline
06/29/16 10:30 AMBrokers Issue Average Price Target Of 19.40 On Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - Fiscal Standard
06/28/16 02:32 PMAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 02:32 PMShare Update and Earnings Review for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Press Telegraph
06/27/16 02:40 PMEquity Research and Technical Review on Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Press Telegraph
06/27/16 07:04 AMNext Weeks Broker Price Targets For Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - Fiscal Standard
06/24/16 02:17 PMNew Broker Ratings For Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - FTSE News
06/22/16 07:28 PMStrong Buy Calls Count For Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) At 3 - Investor Newswire
06/22/16 07:28 PMAdaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Momentum Hits Weakness - CML News
06/22/16 07:06 AMHot Line At Active Movers- Adaptimmune Therapeutics (NASDAQ:ADAP), United Continental (NYSE:UAL), QEP ... - Seneca Globe
06/21/16 02:17 PMStocks to Watch: Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Adaptimmune Therapeutics plc (NASDAQ:ADAP ... - KC Register
06/21/16 02:17 PMAdaptimmune Therapeutics PLC (NASDAQ:ADAP) Receives EMA Orphan Drug Endorsement For SPEAR T-Cell Therapy - Market Exclusive
06/21/16 07:05 AMAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Current Analyst Ratings - Fiscal Standard
06/21/16 06:50 AMADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial -
06/21/16 06:32 AMAdaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System - [GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, June 21, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into ...
06/20/16 08:50 AMAnalyst Views For The Week Ahead: Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - Fiscal Standard
06/20/16 08:50 AMAdaptimmune Therapeutics (ADAP) Announces Positive Opinion for Orphan Drug Designation in EU for SPEAR T-cell ... - StreetInsider.com
06/20/16 08:43 AMAdaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR(TM) T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma - [GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European Medicines ...
06/20/16 08:30 AMAdaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma - [GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, June 20, 2016-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency’ s Committee for Orphan ...
06/17/16 10:14 AMForm 8-K Adaptimmune Therapeutics For: Jun 16
06/16/16 11:49 AMAdaptimmune to Present at the 2016 JMP Life Sciences Conference - [at noodls] - PHILADELPHIA and OXFORD, United Kingdom, June 16, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, ...
06/16/16 05:51 AMADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Sub -
06/15/16 02:20 PMTrend Of Rating Given To Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Investor Newswire
06/08/16 08:25 PMADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Financial Condition Compared to S&P 500 - CML News
06/07/16 07:51 PMAdaptimmune Therapeutics (ADAP) Announces Positive NY-ESO-1 SPEAR T-Cells Data in Multiple Cancers - StreetInsider.com
06/06/16 11:54 AMAdaptimmune Therapeutics PLC (NASDAQ:ADAP) Presents Update on T-cell Receptor Therapy - Market Exclusive
06/06/16 08:44 AMADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/05/16 10:11 AMAdaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at
06/05/16 08:05 AMAdaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting - [GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, June 05, 2016-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced a poster presentation of updated data on its lead clinical ...
06/03/16 02:17 PMCould Adaptimmune Therapeutics PLC - ADR See a Reversal After This Very Strong Session? - HNN
06/02/16 10:45 AMAdaptimmune to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - PHILADELPHIA and OXFORD, United Kingdom, June 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief ...
05/31/16 10:25 AMEmerge Energy Services LP (NYSE:EMES) went down -2.95%: Adaptimmune Therapeutics plc (NASDAQ:ADAP ... - KC Register - Emerge Energy Services LP (NYSE:EMES) went down -2.95%: Adaptimmune Therapeutics plc (NASDAQ:ADAP ...KC RegisterOn 24 May, Adaptimmune Therapeutics plc (NASDAQ:ADAP) disclosed a succession plan for the chairmanship position, which would take effect at the end of the current year. According to the company, in a planned transition of responsibilities, its chairman ...
05/31/16 10:25 AMStock Review and Earnings Check on Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - HNN - Stock Review and Earnings Check on Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Adaptimmune Therapeutics PLC ...and more »
05/30/16 01:54 PMTarget Check and Stock Performance Recap Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - HNN - Target Check and Stock Performance Recap Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)HNNIn recent session activity, Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) shares have traded -1.50%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock ...and more »
05/28/16 11:59 AMAdaptimmune Therapeutics : Announces Succession Plan for Chairman at End of 2016 - (GlobeNewswire) - Adaptimmune Therapeutics plc (Nasdaq:ADAP) (Adaptimmune or the Company), a leader in T-cell therapy to treat cancer, today announced a succession plan for the Chairmanship position that will take effect at the end of 2016. Adaptimmune ...
05/26/16 12:05 PMBRIEF-Adaptimmune Therapeutics says Jonathan Knowles resigned from board - Reuters - BRIEF-Adaptimmune Therapeutics says Jonathan Knowles resigned from boardReutersMay 24 Adaptimmune Therapeutics Plc. * Says Jonathan Knowles resigned from board. * Says David Mott to succeed Knowles, mott now appointed vice chairman of the board. * Says Knowles will step down on Dec, 2016, and will be succeeded as chairman ...
05/26/16 12:05 PMAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Unveils Chairmanship Succession Plan, SPEAR T-cells Brand - Market Exclusive - Market ExclusiveAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Unveils Chairmanship Succession Plan, SPEAR T-cells BrandMarket ExclusiveAdaptimmune Therapeutics plc (NASDAQ:ADAP) announced on Tuesday its chairmanship succession plan that will take effect by the end of the year. According to the biopharmaceutical company, Dr. Jonathan Knowles, Adaptimmune Chairman, will step ...Adaptimmune Reveals Succession Plan For ChairmanBenzingaAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Quarterly EPS From Continuing Operations Stands At $-0.22Enterprise Leaderall 3 news articles »
05/24/16 02:32 PMAdaptimmune Reveals Succession Plan For Chairman - Adaptimmune Therapeutics PLC - ADR (NASDAQ: ADAP) disclosed a succession plan for the chairmanship position, which would take effect at the end of the current year. According to the company, in a planned transition of responsibilities, its chairman, Jonathan Knowles, would step down from the board on December 31. The company added that David Mott would succeed as chairman from January 1 next year. Adaptimmune said that Mott has been named as vice-chairman for the duration of the transition period. The company indicated that he has served as a non-executive director of Adaptimmune since September 2014. The company said that Knowles served as a non-executive director of Adaptimmune since September 2011 and as chairman since November 2013. The company has ...Full story available on Benzinga.com
05/24/16 08:56 AMADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and -
05/24/16 06:46 AMAdaptimmune Announces Succession Plan for Chairman at End of 2016 - [at noodls] - PHILADELPHIA and OXFORD, United Kingdom, May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) ('Adaptimmune' or the 'Company'), a leader in T-cell therapy to treat cancer, today ...
05/19/16 10:02 AMAdaptimmune to Present at the 2016 UBS Global Healthcare Conference - [at noodls] - PHILADELPHIA and OXFORD, United Kingdom, May 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief ...
05/12/16 07:15 AMADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/12/16 06:47 AMAdaptimmune Reports First Quarter 2016 Financial Results - [at noodls] - PHILADELPHIA and OXFORD, United Kingdom, May 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) ('Adaptimmune' or the 'Company'), a leader in T-cell therapy to treat cancer, today ...
05/08/16 01:47 PMAfter Last Week What Do Analysts Think Of Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - Share Trading News - After Last Week What Do Analysts Think Of Adaptimmune Therapeutics Plc (NASDAQ:ADAP)Share Trading News12/22/2015 – SunTrust began new coverage on Adaptimmune Therapeutics plc giving the company a “buy” rating. They now have a USD 16 price target on the stock. 10/15/2015 – Adaptimmune Therapeutics plc had its “outperform” rating reiterated by ...
05/04/16 01:50 PMMarket Movers: North Atlantic Drilling(NYSE:NADL), Adaptimmune Therapeutics (NASDAQ:ADAP), Forestar Group Inc ... - KC Register - Market Movers: North Atlantic Drilling(NYSE:NADL), Adaptimmune Therapeutics (NASDAQ:ADAP), Forestar Group Inc ...KC RegisterAdaptimmune Therapeutics plc (NASDAQ:ADAP), announced that Adrian Rawcliffe, Chief Financial Officer of Adaptimmune, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 11:20 AM PDT (7:20 PM ...
05/04/16 01:50 PMAverage Analyst Rating for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - B.O.D.Y Confidential - Average Analyst Rating for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.5 on Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by ...and more »
05/04/16 01:50 PMAdaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) Shorted Shares Decreased By 11.98% - B.O.D.Y Confidential - Adaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) Shorted Shares Decreased By 11.98%B.O.D.Y ConfidentialThe stock of Adaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) registered a decrease of 11.98% in short interest. ADAP's total short interest was 1.00 million shares in May as published by FINRA. Its down 11.98% from 1.14 million shares, reported ...and more »
05/03/16 08:30 AMAdaptimmune to Present at the Bank of America Merrill Lynch 2016 Health Care Conference - [at noodls] - PHILADELPHIA and OXFORD, United Kingdom, May 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, ...
04/27/16 12:57 PMAdaptimmune to Present at the Deutsche Bank Securities 41st Annual Health Care Conference - [at noodls] - PHILADELPHIA and OXFORD, U.K., April 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that ...
04/24/16 01:36 PMLatest Analyst Ratings For Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - Share Trading News - Web Breaking NewsLatest Analyst Ratings For Adaptimmune Therapeutics Plc (NASDAQ:ADAP)Share Trading News12/22/2015 – SunTrust began new coverage on Adaptimmune Therapeutics plc giving the company a “buy” rating. They now have a USD 16 price target on the stock. 10/15/2015 – Adaptimmune Therapeutics plc had its “outperform” rating reiterated by ...Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Has Been Given An ABR Of 1.5Equities FocusAdaptimmune Therapeutics PLC - (NASDAQ:ADAP) Receives $16.30 Consensus PT from BrokeragesWeb Breaking NewsAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Analyst Rating ReviewB.O.D.Y Confidentialall 4 news articles »
04/22/16 12:02 PMAdaptimmune Presents Corporate and Clinical Updates at Investor and Analyst Day - [at noodls] - PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today hosted ...
About Adaptimmune Therapeutics PLC -

Adaptimmune Therapeutics PLC - logoAdaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company's TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADAP
  • CUSIP:
Key Metrics:
  • Previous Close: $8.26
  • 50 Day Moving Average: $9.53
  • 200 Day Moving Average: $8.96
  • P/E Ratio: N/A
  • P/E Growth: 0.27
  • Market Cap: $584.68M
  • Current Quarter EPS Consensus Estimate: $-1.29 EPS
Additional Links:
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha